An interventional study of The BRAIN App in Dementia, Alzheimer Disease and Vascular Dementia, sponsored by Hopeful Aging. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Hopeful Aging · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.
Among the 1,051 studies in Dementia with a site in United States, this one is the 359th largest by planned enrollment of the 846 interventional ones that give a count, is one of 61 that started in 2025, is one of 562 with no phase, reaches primary completion later than 74 of the 275 other live ones, and was the 877th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 21+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,051 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 61 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 93 across the 846 interventional studies, 200 across the 200 observational. Of the 715 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,051 have an industry lead sponsor. The 10 most frequent:
Hopeful Aging is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Hopeful Aging has 5 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
107 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 107 to your calendar (.ics) → With an account.
Among the 1,051 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Association, 2018). Responsive behaviors and dysfunction of the dementia care triad-i.e., the PLWD, professional Care Partner (CP), and Family Member (FM)-are inexorably linked. The emergence of responsive behaviors can lead to disruption of the triad's function. Thus, it is imperative to maintain positive relationships and a high quality of life (QoL) within the triad to reduce BPSD. Cognitive Stimulation Therapy (CST) has demonstrated improvements in QoL and relationships for PLWD. CST is a psychosocial intervention that promotes communication and engagement in PLWD via a structured program of meaningful and enjoyable theme. While clinical trials have shown improvement in cognition and QoL, the potential large-scale impact of CST has been hampered by low adherence, with less than 40% completing trials. One likely reason for the low adherence to CST is the reliance on generic and non-digital tools (e.g., paper-based agendas, tools, DVDs, and board games) in facilitating the intervention. That is, even though CST aims to be personalized, the specific interventions used in the field tend to be generic and not tailored to each PLWD's specific interests. The use of digital technology to implement CST would offer considerable advantages to expand and personalize the range of stimulation content and provide a means for monitoring responses, optimizing protocols, and promoting adherence.
The proposed Phase II study will involve the continued development and evaluation of a multi-faceted software platform called "Building Relationships using Artificial Intelligence and Nostalgia" or BRAIN. The BRAIN Platform will be the first-ever Artificial Intelligence (AI) powered CST digital therapy platform for PLWD. The platform, which has been shown to be effective in an initial Phase I clinical trial, has three main goals: to improve the quality of life of PLWD, to reduce BPSD in PLWD, and to foster positive relationships between members of the care triad. The proposed Phase II project has the following Specific Aims: 1. Create an improved Beta version of the BRAIN Platform's eight components: (1) the Admin Management Dashboard, (2) the Annotation Dashboard, (3) the Log Viewer, (4) the Content Management System (CMS), (5) the Private CMS, (6) the Control App, (7) the Home App, and (8) the Training Dashboard. 2. Fine-tune the different classes of AI algorithms-i.e., behavioral analytics, personalized content recommendation, and personalized program generation-in the BRAIN app such that they can (a) recognize and track 12 distinct behaviors and indicators of PLWD, (b) use these behavioral traits as a basis for automatically rating the relative success of each activity, and (c) automatically recommend personalized activities that are likely to be successful for individual PLWD. 3. Conduct a Cluster Randomized Trial (CRT) of the BRAIN App to examine the app's impact on engagement/affect, quality of life, and responsive behaviors. 4. Examine satisfaction and ease of use of the app for PLWD, LTC staff, and FMs.
Sample Sample PLWD, The primary sample will consist of 120 PLWD-i.e., at each of the 8 LTC facilities, 15 PLWD will participate in the study (8 sites x 15 PLWD = 120 PLWD). Half of the PLWD (n=60) will be in the Experimental Group and the other half (n=60) will be in the Control Group. PLWD will be split equally between NHs and ALFs, so sample sizes will be as follows for each site type/condition: Experimental NH, n=30; Experimental ALF, n=30; Control NH, n=30; Control ALF, n=30. Family Members For each PLWD living at an Experimental Site, one family member will participate in the study. As such, 60 Family Members will participate in the study. Family Members will facilitate the BRAIN intervention twice per month and provide feedback related to satisfaction and ease of use. Staff Members At each Experimental Site, 6 staff members will participate, including 1 administrator/executive director, 1 activity staff member, and 3 CPs. Since there are four Experimental Sites, 24 staff members will participate. Staff members will take the BRAIN Training Modules, use the BRAIN Platform at least twice, and provide feedback related to satisfaction and ease of use. Diversity: As was true in Phase I, we are committed to testing the app with a diverse sample.
Study Design The study will utilize a quasi-experimental pre-post design-i.e., baseline vs. treatment / post-treatment.
Inclusion/Exclusion Criteria Inclusion Criteria: PLWD, 65+ years old, dementia diagnosis (any type), and able to speak conversational English; Family/Staff Members, 18+ years old and able to speak English. (Activity content/questionnaires will be in English).
Exclusion Criteria PLWD, completely unable to communicate verbally, serious visual or hearing impairments, and/or signs of rapid decline over the last three months (based upon staff report); Family/Staff Members, none.
Analyses Primary Outcomes: Engagement/affect, quality of life, and responsive behaviors/BPSD.
Secondary Outcomes: Cognition, depression, and quality of the relationship between the family member and PLWD.
The BRAIN Platform will be considered successful if the following results are found:
B. Study Procedures, Materials, and Potential Risks Measures Baseline Data Collection Period: PLWD: Data related to demographics, meds, diagnoses, and type of dementia will be collected via chart review. The following assessments will be administered directly to PLWD: the Mini-Mental Status Examination, the Dementia Quality of Life Scale, and the Geriatric Depression Scale-Short Form. In addition, a researcher will ask the PLWD 20 questions to learn about his/her background, interests, and preferences. Researchers will interview LTC facility CPs to implement the Neuropsychiatric Inventory-Nursing Home. FMs A researcher will interview each FM to collect demographics and to implement the Quality of Carer-patient Relationship (QCPR) measure, which measures warmth and/or absence of conflict or critique on a 5-point scale (Sprite et al, 2002). FMs will also be asked to fill out an online form to provide information about their loved one's background, interests, and preferences, etc. If preferred, he/she will be able to provide this information via a phone interview. Info about the PLWD information will be used to automatically recommend activities based upon the person's background, interests, and preferences. FM will also take pre-quizzes related to the BRAIN Training Modules. Staff Members A researcher will interview each staff member to collect demographics. Staff will also take pre-quizzes related to the Training Modules.
During the 4-week baseline data collection period, researchers will observe PLWD's engagement and affect during standard, staff-led activities using the MPES and the EPWDS. To ensure a robust comparison for treatment programming, each participant will be observed at least 12 times with each measure, so that means can be calculated for each type of engagement/affect. Staff members will be trained extensively on both measures prior to the commencement of the study. and interrater reliability of at least 85% will be maintained and audited during the study.
Intervention Period Data Collection Period: During a 3-month intervention period, PLWD will be invited to use the app three times per week. Four Nursing Assistants (NAs)--one for each Experimental site-will implement the intervention as individual activity sessions lasting 20-30 minutes with the PLWD. Most activity sessions will be implemented by the NAs. However, two activity sessions per month for each PLWD be implemented by the PLWD's family members. (Please note: In previous studies the study team has successfully engaged family members to participate in trials and are certain that this level of engagement is feasible in this trial.) In addition, LTC staff members will use the app at least twice during the intervention session (with any PLWD at his/her facility), so that they can provide feedback about the BRAIN platform. Please note: prior to using the BRAIN Platform, the NAs, FMs, and Staff Members will take the BRAIN Training Modules, so that they know how to successfully facilitate activities with PLWD and know how to use the BRAIN Platform itself. During initial activity sessions, the AI will automatically recommend activity content based upon the PLWD's background, interests, and preferences. After this, the AI will also consider the relative success of previously implemented activity sessions.
During each activity session, researchers will observe the PLWD using the MPES and EPWDS. Observations will be conducted via video, since each activity session will be automatically video recorded by the Home App. (Video consent will be obtained from the person responsible for the PLWD's medical decisions.) Session length and time of day will also be noted. Three satisfaction questions will be posed to PLWD at the end of each session: (1) did you enjoy this activity? (2) would you like to do an activity like this again sometime? and (3) would you recommend this activity to others? The same three satisfaction questions will be posed to FMs and LTC Staff Members each time they facilitate a BRAIN activity.
Post-Treatment Data Collection Period: For PLWD, the MMSE, DEMQOL, GDS-SF, and NPI-NH will be implemented again after the Intervention Period is complete. This will allow us to investigate whether any long-term effects are seen. FMs will take post-training quizzes after completing the training modules and fill out the QCPR again. Staff Members will take post-training quizzes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PLWD in the Experimental Group will be invited to use the BRAIN intervention twice per week for 3 months. Each session is expected to last 20-30 minutes. The BRAIN app will initially recommend activities for each PLWD based upon his/her background/interests/preferences, which will be collected when the PLWD first enrolls in the study. After the initial sessions, the BRAIN app will use AI to recommend new activities for subsequent sessions. These recommendations will be based upon the AI's rating of the relative success or failure of the activities initially provided to the PLWD.
Behavioral: The BRAIN App
PLWD in the Control Group will participate in standard care / programming for 3 months.
The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
Menorah Park Engagement Scale (MPES)
The Menorah Park Engagement Scale measures four types of engagement. Constructive Engagement, Passive Engagement, Other Engagement, and Non-Engagement. It also measures pleasure. Scores on each type of engagement item range from 0 to 2 with higher scores indicating a better outcome for Constructive Engagement, Passive Engagement, and Pleasure. Higher scores represent worse outcomes for Distracted and Non Engagement.
Time frame: Baseline, that is, Weeks 1 - 4
Menorah Park Engagement Scale (MPES)
The Menorah Park Engagement Scale measures four types of engagement. Constructive Engagement, Passive Engagement, Other Engagement, and Non-Engagement. It also measures pleasure. Scores on each type of engagement item range from 0 to 2 with higher scores indicating a better outcome for Constructive Engagement, Passive Engagement, and Pleasure. Higher scores represent worse outcomes for Distracted and Non Engagement.
Time frame: Intervention Period, that is, Weeks 5-16
Engagement for Persons with Dementia Scale (EPWDS)
This scale measures the engagement in 5 domains: affective, visual, verbal, behavioral and social. Scores range from zero (0) to 36 with higher scores indicating a better outcome.
Time frame: Baseline, that is, Weeks 1 - 4
Engagement for Persons with Dementia Scale (EPWDS)
This scale measures the engagement in 5 domains: affective, visual, verbal, behavioral and social. Scores range from zero (0) to 36 with higher scores indicating a better outcome.
Time frame: Baseline, that is, Weeks 5-16
Dementia Related Quality of Life (DEMQOL)
The DEMQOL measures quality of life, composed of 28 items. Scores range from zero (0) to 112. Higher scores represent better outcomes.
Time frame: Baseline, that is, Weeks 1 - 4
Dementia Related Quality of Life (DEMQOL)
The DEMQOL measures quality of life, composed of 28 items. Scores range from zero (0) to 112. Higher scores represent better outcomes.
Time frame: Post-Intervention, that is, Weeks 17-18
Neuropsychiatric Inventory--Nursing Home (NPI-NH)
The NPI-NH measures 12 types of neuropsychiatric symptoms, including their severity and frequency. The total score for F x S ranges from 0 to 120. Lower scores indicate better outcomes.
Time frame: Baseline, that is, Weeks 1 - 4
Neuropsychiatric Inventory--Nursing Home (NPI-NH)
The NPI-NH measures 12 types of neuropsychiatric symptoms, including their severity and frequency. The total score for F x S ranges from 0 to 120. Lower scores indicate better outcomes.
Time frame: Post-Intervention, that is, Weeks 17-18
Quality of Carer-Patient Relationship (QCPR)
This 14-item scale measures warmth and/or absence of conflict or critique on a 5-point scale Scores range from zero (0) to 56, with higher scores indicating better outcomes.
Time frame: Baseline, that is, Weeks 1 - 4
Quality of Carer-Patient Relationship (QCPR)
This 14-item scale measures warmth and/or absence of conflict or critique on a 5-point scale Scores range from zero (0) to 56, with higher scores indicating better outcomes.
Time frame: Post-Intervention, that is, Weeks 17-18
Mini-Mental Status Examination (MMSE) Mini-Mental Status Examination (MMSE)Mini-Mental Status Examination (MMSE)
The MMSE measures cognition. The possible scores range from 0 to 30, with high scores indicating a better outcome. A common cutoff for dementia is 23 or lower.
Time frame: Baseline, that is, Weeks 1 - 4
Mini-Mental Status Examination (MMSE) Mini-Mental Status Examination (MMSE)Mini-Mental Status Examination (MMSE)
The MMSE measures cognition. The possible scores range from 0 to 30, with high scores indicating a better outcome. A common cutoff for dementia is 23 or lower.
Time frame: Post-Intervention, that is, Weeks 17-18
Plan to share: Undecided — This is TBD.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 46 industry-sponsored interventional studies with no phase under Dementia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 18 months is close to that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopeful Aging